Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2016 08:00 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Submits Investigational New Drug Application to Conduct Studies in Cervical, Head and Neck Cancer

NEW YORK, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
December 21, 2015 08:00 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Enters Clinical and Preclinical Research Collaboration With MedImmune

NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
December 15, 2015 08:00 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces Selection for Addition to NASDAQ Biotechnology Index

NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
November 16, 2015 08:00 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies to Participate in Upcoming Investor Conferences

NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
November 09, 2015 08:00 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces Agreement With WuXi AppTec to Increase TIL Manufacturing Capacity

NEW YORK, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
November 05, 2015 08:00 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces Third Quarter 2015 Financial Results

NEW YORK, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq: LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
November 02, 2015 08:00 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi

NEW YORK, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
October 07, 2015 08:01 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers

NEW YORK, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL),...
September 16, 2015 14:16 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Announces Positive Updated Data From NCI's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma

NEW YORK, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...
September 14, 2015 08:00 ET | Source: Lion Biotechnologies, Inc.

Lion Biotechnologies Opens Enrollment in Phase 2 Study of LN-144 for the Treatment of Refractory Metastatic Melanoma

NEW YORK, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO) a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes...